Actively Recruiting
Improvement of Depression With Use of ATP
Led by Nanfang Hospital, Southern Medical University · Updated on 2024-03-19
120
Participants Needed
1
Research Sites
147 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical study is a randomized, double-blind, placebo-controlled trial with an intervention period of 4 weeks. Participants will be patients with moderate to severe depression who meet the inclusion criteria during the screening period. After recruitment written informed consent form will be signed and the baseline evaluation will be done then the treatment period follows. The subjects will be randomly assigned to a control group (escitalopram plus normal saline(NA)) and an ATP group (escitalopram plus adenosine disodium triphosphate(ATP)) in a 1:1 ratio for treatment, with a total number of 120 recruited patients. Assessment will be carried out as an analysis of changes in Hamilton Depression Scale（HAMD-24）, cognitive function test, brain functional network, inflammatory markers, and other indicators in the first, second, and fourth week of intervention which will evaluate the effectiveness of ATP in improving moderate to severe depression preliminarily.
CONDITIONS
Official Title
Improvement of Depression With Use of ATP
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Meet the diagnostic and statistical manual of mental disorders-5 diagnostic criteria for moderate to severe depression.
- HAMD-24 scores 20.
- Age between 18 and 65 years, female or male.
- No use of psychotropic medications within one month prior to study and no prior treatment with escitalopram.
- No contraindications to selective serotonin reuptake inhibitors.
- No contraindications to ATP.
- Signed written informed consent.
You will not qualify if you...
- Presence of major mental disorders other than depression, including bipolar disorder, psychotic disorders, personality disorders, alcohol use disorder, substance use disorder, or disorders due to medical or organic causes.
- Neurological disorders such as dementia.
- High risk of suicide.
- Pregnant or lactating women.
- Contraindications to MRI.
- Deemed unsuitable for the study by physician evaluation.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510515
Actively Recruiting
Research Team
B
Bin Zhang, PhD
CONTACT
Q
Qianqian Xin, MMed
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here